{"organizations": [], "uuid": "95874110c6d13f4adabf5f7878a17d95d6ee585b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-xencor-inc-expect-initial-data-fro/brief-xencor-inc-expect-initial-data-from-phase-2-trial-of-xmab5871-in-systemic-lupus-erythematosus-idUSFWN1P00S1", "country": "US", "domain_rank": 408, "title": "BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab速5871 In Systemic Lupus Erythematosus", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T15:18:00.000+02:00", "replies_count": 0, "uuid": "95874110c6d13f4adabf5f7878a17d95d6ee585b"}, "author": "", "url": "https://www.reuters.com/article/brief-xencor-inc-expect-initial-data-fro/brief-xencor-inc-expect-initial-data-from-phase-2-trial-of-xmab5871-in-systemic-lupus-erythematosus-idUSFWN1P00S1", "ord_in_thread": 0, "title": "BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab速5871 In Systemic Lupus Erythematosus", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-xencor inc", "sentiment": "negative"}, {"name": "systemic lupus erythematosus reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "xencor inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 5, 2018 / 1:18 PM / Updated 5 minutes ago BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab速5871 In Systemic Lupus Erythematosus Reuters Staff 1 Min Read \nJan 5 (Reuters) - Xencor Inc: \n* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB速5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS \n* XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)", "external_links": [], "published": "2018-01-05T15:18:00.000+02:00", "crawled": "2018-01-05T15:36:59.005+02:00", "highlightTitle": ""}